Literature DB >> 10698308

Non-anaphylactic combination of partially deleted fragments of the major house dust mite allergen Der f 2 for allergen-specific immunotherapy.

T Takai1, A Mori, T Yuuki, H Okudaira, Y Okumura.   

Abstract

Allergen-specific immunotherapy, in which repeated injections of allergens over prolonged periods are used to induce tolerance, has proven an effective treatment of allergy. A major side effect of allergen-specific immunotherapy is anaphylactic reaction. House dust mite allergens are major causative factors associated with various allergic diseases. Der f 2 is the major house dust mite allergen composed of 129 amino acid residues. Analysis using deletion mutants of Der f 2 suggested that T-cell epitopes of Der f 2 were multiple in mite-allergic patients. We found that some IgE epitopes were renatured by dialysis of a mixture of two denatured C- and N-terminal deletion mutants, 1-112 and 85-129 in 13 patients out of 14. On the other hand, IgE binding activity was negative in the separately dialyzed fragments and their mixture in each patient tested. Furthermore, we demonstrated that neither of the two separately prepared polypeptides induced in vivo skin prick test reactivity. These findings are important for improvement of T-cell targeting allergen-specific immunotherapy and development of monovalent IgE haptens. The use of combinations of overlapping non-anaphylactic fragments of allergen covering all of the T-cell epitopes achieves the removal of IgE reactivity, the cause of harmful anaphylactic reactions, without affecting the T-cell reactivity essential for immunotherapy, offering potentially safer and more effective treatment for allergic disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10698308     DOI: 10.1016/s0161-5890(99)00098-x

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  7 in total

Review 1.  Structural characterization of pollen allergens.

Authors:  Petra Verdino
Journal:  Clin Rev Allergy Immunol       Date:  2006-04       Impact factor: 8.667

2.  Immunoproteomic analysis of house dust mite antigens reveals distinct classes of dominant T cell antigens according to function and serological reactivity.

Authors:  Carla Oseroff; Lars H Christensen; Luise Westernberg; John Pham; Jerome Lane; Sinu Paul; Jason Greenbaum; Thomas Stranzl; Gitte Lund; Ilka Hoof; Jens Holm; Peter A Würtzen; Kåre H Meno; April Frazier; Veronique Schulten; Peter S Andersen; Bjoern Peters; Alessandro Sette
Journal:  Clin Exp Allergy       Date:  2016-11-07       Impact factor: 5.018

3.  Hypoallergenic Der p 1/Der p 2 combination vaccines for immunotherapy of house dust mite allergy.

Authors:  Kuan-Wei Chen; Katharina Blatt; Wayne R Thomas; Ines Swoboda; Peter Valent; Rudolf Valenta; Susanne Vrtala
Journal:  J Allergy Clin Immunol       Date:  2012-07-11       Impact factor: 10.793

4.  Carrier-bound nonallergenic Der p 2 peptides induce IgG antibodies blocking allergen-induced basophil activation in allergic patients.

Authors:  K-W Chen; M Focke-Tejkl; K Blatt; M Kneidinger; A Gieras; F Dall'Antonia; I Faé; G Fischer; W Keller; P Valent; R Valenta; S Vrtala
Journal:  Allergy       Date:  2012-02-17       Impact factor: 13.146

5.  Expression of hypoallergenic Der f 2 derivatives with altered intramolecular disulphide bonds induces the formation of novel ER-derived protein bodies in transgenic rice seeds.

Authors:  Lijun Yang; Sakiko Hirose; Kazuya Suzuki; Takachika Hiroi; Fumio Takaiwa
Journal:  J Exp Bot       Date:  2012-02-29       Impact factor: 6.992

6.  Immunotherapeutic efficacy of liposome-encapsulated refined allergen vaccines against Dermatophagoides pteronyssinus allergy.

Authors:  Urai Chaisri; Anchalee Tungtrongchitr; Nitaya Indrawattana; Panisara Meechan; Watchara Phurttikul; Natt Tasaniyananda; Nawannaporn Saelim; Wanpen Chaicumpa; Nitat Sookrung
Journal:  PLoS One       Date:  2017-11-28       Impact factor: 3.240

7.  Recombinant house dust mite allergens.

Authors:  Susanne Vrtala; Hans Huber; Wayne R Thomas
Journal:  Methods       Date:  2013-07-31       Impact factor: 3.608

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.